Vertex (VRTX) PT Lowered to $522 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- Six killed in cyclone off India's eastern coast
- Amazon (AMZN) Misses Q3 EPS by 7c, Misses on Revenue; Offers Q4 Revenue Guidance
- Sandisk announces 8-for-1 forward stock split effective November 2026
- Reddit, Inc. (RDDT) Tops Q3 EPS by 7c, Beats on Revenue; Offers Q4 Revenue Guidance
- SanDisk stock falls ahead of earnings report
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Evercore ISI on Vertex (VRTX): 'we see upside from here in 2025'
December 19, 2024 2:58 PM ESTEvercore ISI analyst Liisa Bayko reiterated an Outperform rating and $515.00 price target on Vertex (NASDAQ: VRTX).
The analyst comments "Below we share our thoughts and some nuggets from our back and forth with VRTX following the call today No change to our modelwe continue to view LSR as upside. Understanding the high PBO response, which was clinically significant in and of itself and higher than the P3 pregabalin LSR study (see chart inside). There was more use of NSAIDS in the low placebo responders, but we dont quite... More



